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Purpose: COX-2 overexpression and elevated levels of prostaglandin E2 (PGE2) play an
important role in breast cancer carcinogenesis. Recently, expression of the PGE2 receptor
EP3 has been shown to be a positive prognostic factor in breast cancer. This study analyzes
the functional aspects of targeting EP3 in breast cancer cell lines.
Material and methods: EP3 and EP1 expressions were determined in five breast cancer
cell lines on the mRNA- and the protein-level. The selected cell lines were subsequently
stimulated for 24–72 hrs with 10–1,000 nM of PGE2, the EP1/EP3 agonist sulprostone and
the EP3 antagonist L798,106. Cell proliferation was determined via BrdU-assay, migration
via scratch assay, EP3, Gi-protein and p-ERK1/2 expressions via Western blot and cAMP
concentrations via ELISA. The Mann–Whitney-U-test was used to test for statistical
significance.
Results: The cell lines T-47D (EP3 expression 77.7%) and SK-BR-3 (EP3 expression 48.7%)
were chosen. EP3 antagonism reduced its expression on SK-BR-3 significantly, while no effect
was observed on T-47D. The proliferation and migration of SK-BR-3 cells were significantly
reduced due to treatment with the EP1/3 agonist, the EP3 antagonist or a combination of both.
Neither agonism nor antagonism influenced cell proliferation or migration in T-47D. In SK-
BR-3, EP3 antagonism showed a significant decrease in Gi-protein levels, an increase in cAMP
levels, and no significant change in p-ERK1/2 expression.
Conclusion: Antagonism of the EP3 receptor results in a reduced proliferation and migra-
tion of SK-BR-3 breast cancer cells, potentially mediated via a Gi-protein-cAMP pathway.
The results suggest that EP3 plays a role in tumorigenesis. This is in accordance with the cell
culture data of other gynecological tumors, but it is conflicting in so far, as positive EP3
expression is clinically a positive prognostic marker in breast cancer. Therefore, other factors
may be important in explaining this contradiction.
Keywords: carcinoma of the breast, prostaglandin E2 receptor 3, cell growth, cell traffic,
signal transduction, in vitro experiments
Introduction
Breast cancer represents the most common malignancy in women worldwide. In the
United States, 268,600 newly diagnosed cases of breast cancer and 41,760 deaths
are estimated for 2019.1 Despite advances in the treatment of early-stage breast
cancer, 10–15% of breast cancer patients develop distant metastases within 3 years
after the detection of the primary tumor.2 A French observation cohort found that
within the past decade the overall survival in metastatic breast cancer has ranged
around 37 months.3 Known negative prognostic factors in breast cancer include
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positive axillary lymph nodes,4 negativity for estrogen or
progesterone receptor,5 a high tumor proliferation rate
measured by Ki-67,6 and the amplification of the Her-2
oncogene. Her-2 is a protein that promotes growth and
proliferation of tumor cells leading to an impaired prog-
nosis for patients with Her-2 enriched tumors.7 However,
due to the innovation of specific Her-2-targeting drugs, the
prognosis of Her-2 positive patients has changed dramati-
cally. In fact, patients with metastatic Her-2 positive dis-
ease are now showing the best survival rates of all
metastatic breast cancer subtypes.3,8,9 Nevertheless, espe-
cially for the triple negative subtype that has the worst
prognosis of all breast cancer subtypes,3,9 targeted thera-
pies are still lacking. The search for targetable prognostic
factors is ongoing.
In different kinds of cancer, chronic inflammation repre-
sented by cyclooxygenase (COX)-2 overexpression and by
elevated levels of prostaglandin E2 (PGE2) has been asso-
ciated with tumor development and progression.10
Prostaglandins belong to the group of eicosanoids. These are
tissue hormones with essential functions in several physiolo-
gical processes as well as in inflammatory processes and in
tumor development.10 The prostaglandin synthesis is depen-
dent on COX-enzymes which catalyze the conversion of ara-
chidonic acid to prostaglandin G2; the precursor molecule for
the synthesis of PGE2 and other eicosanoids. While the COX-
1 enzyme is expressed constitutively, the COX-2 expression is
induced by various cytokines and growth factors.11
Chronic inflammation marked by elevated levels of
PGE2 has been shown in breast cancer. Overexpression of
COX-2 was observed in 40% of invasive breast cancer
cases.11,12 An elevated COX-2 expression has been asso-
ciated with impaired disease-free survival. Furthermore, the
tumor biology of COX-2 elevated tumors is more aggres-
sive, demonstrated by a higher grading, and a higher pro-
liferation rate identified by Ki-67.13 The importance of the
COX-2-PGE2 axis has been confirmed in several studies.
The inhibition of the COX-2 enzyme with selective COX-2
inhibitors (COXibs) – in experimental mouse models14 as
well as in a case-control patient study15 – has been success-
ful in reducing tumor progression or the risk of breast
cancer development. However, the clinical use of COXibs
is limited, due to their associated cardiovascular side
effects, like thrombosis and embolism. These are probably
caused by an imbalance of pro- and anti-aggregatory agents
due to the selective depression of the prostacyclin synthesis
via COX-2 while the thromboxane synthesis via COX-1 is
maintained.12
PGE2 exerts its effects by signaling via the G protein-
coupled PGE2-receptors EP1–4.16 Concerning their role in
breast cancer, EP2 and EP4 are the best evaluated receptors
and are mainly assumed to be negative prognostic factors in
breast cancer.17–19 The role of EP1 in breast cancer is less
well understood. Some authors discuss divergent effects in
tumor development and progression: EP1 has been shown
to be tumor promoting concerning primary breast cancers in
rats.20 In contrast, it did also show suppressing effects on
breast cancer metastases.21 The EP3 receptor is the least
well-understood receptor in breast cancer. We were recently
able to demonstrate that EP3 expression in primary sporadic
breast cancer is associated with improved progression-free
survival and improved overall survival.22 This is surprising
since a high EP3 expression has been associated with an
impaired prognosis in other gynecological tumors, like cer-
vical cancer23 or endometrial cancer.24 Endometrial cancer
cells showed a reduced proliferation and migration due to
EP3 antagonism.24
EP3 exists in various isoforms generated by alternative
mRNA splicing.11 This could partly explain different
effects of EP3 in different tumors, but tumor-type specific
EP3-functions could play an important role as well.
Several signaling pathways downstream of EP3 have
been identified.25 It is assumed that some specific EP3
isoforms couple to a Gs protein and increase cyclic ade-
nosine monophosphate (cAMP) levels via adenylate
cyclase (AC) induction.26 Other EP3-isoforms couple to
a Gi-protein and decrease cAMP levels.27 Furthermore, the
EP3-receptor can signal via phosphatidylinositol 3-kinase
(PI3K) and via the phosphorylation of extracellular signal-
regulated kinases 1/2 (ERK1/2).28
As described above, we could recently demonstrate the
positive prognostic effect of a high EP3-expression in
breast cancer patients, while the underlying mechanisms
remain unclear.22 The present study now aims to elucidate
the functions of the EP3 receptor in breast cancer using a
breast cancer cell culture model.
Materials and methods
Cell culture and drugs
The breast cancer cell lines used in this study were
obtained from the American Type Culture Collection
(Manassas, VA, USA) and are listed in Table 1.
The cells were maintained in RPMI 1640 Medium
+GlutaMAX (Thermo Fisher, Waltham, MA, USA) com-
plemented with 10% FBS (Thermo Fisher, USA). The
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cells were incubated at 37°C and 5% CO2 saturation. As
preparation for each experiment, the cells were counted
using Neubauer cell chambers, seeded in 6–96 well plates
and incubated overnight. After 24 hrs, the cell culture
medium was replaced by fresh RPMI 1640 medium
+GlutaMAX, containing dimethylsulfoxide (DMSO,
0.1%) as a vehicle control or 10–1,000 nM of PGE2
(Tocris Bioscience, Ellisville, MI, USA), sulprostone
(Tocris Bioscience) or L798,106 (Tocris Bioscience).
L798,106 is a selective EP3 antagonist whereas sulpros-
tone is described as a dual EP1/EP3 agonist.29 The selec-
tive EP3 agonist ONO-AE-248 was not available (not in
stock anymore).30
mRNA expression
The EP1 receptor expression and the EP3 receptor expres-
sion on mRNA-level in MDA-MB-231, SK-BR-3, T-47D,
MCF-7 and CAMA-1 breast cancer cells lines were deter-
mined using quantitative real-time-(RT)-PCR. The RNeasy
Mini Kit (Qiagen, Hilden, Germany) was used to obtain
the total RNA from cultured cells. The RNA was con-
verted to cDNA with an MMLV Reverse Transcriptase
First-Strand cDNA synthesis kit (epicenter, Madison,
Wisconsin, USA) according to manufacturer’s instruc-
tions. For the RT-PCR, 20 µL reaction mixture (1 µL
TaqMan® Gene Expression Assay 20×[Applied
Biosystems, target ACTB, Nr. Hs99999903_m1, target
PTGER3, Nr. Hs00168755_m1, or target PTGER1, Nr.
Hs00168752_m1, primer sequences are not available due
to the use of a commercial assay], 10 µL TaqMan® Fast
Universal PCR Master Mix 2×[Applied Biosystems], 1 µL
cDNA template and 8 µL RNase free water) per sample
were given on a 96-well plate (Applied Biosystems) and
were covered by an optical adhesive film. A 7500 Fast
Real-time PCR system (Applied Biosystems) was used to
run the PCRs. Initially, for the enzyme activation, heating
to 95°C for 20 s was performed, followed by 40 qPCR-
cycles of 3 s of denaturation at 95°C and annealing for 30
s at 60°C. The comparative 2−ΔΔCT method was used to
analyze the results. β-actin was used as an endogenous
control for ΔCT-values and the results are means of tripli-
cates in two independent measurements.
Western blot
Western blot analyses were performed to analyze protein
expression levels. The EP1 and the EP3 expression were
analyzed in unstimulated SK-BR-3 and T-47D cells, the
EP3 expression was analyzed in unstimulated MDA-MB-
231 cells. In T-47D cells, the EP3 expression was also
analyzed after stimulation as described below. After sti-
mulation (as described below) of SK-BR-3 cells, the
expression of EP3, Gi-protein and p-ERK1/2 was mea-
sured. SK-BR-3 and T-47D cells were treated with 10,
100 or 1,000 nM of PGE2, sulprostone or L798,106 for
1–24 hrs (1 hr for p-ERK1/2-expression; 24 hrs for EP3-
and Gi-protein-expression). A cell sample incubated with
DMSO (0.1%) served as a vehicle control. After stimula-
tion, 200 µL of RIPA buffer (Sigma-Aldrich, R0278-
50ML) were added and the samples were kept at −20°C
for 10 mins to create protein samples. The protein aliquots
were prepared in 4×Laemmli loading buffer. The samples
were loaded on a 10% polyacrylamide gel (SDS-Page) and
separated at a constant voltage of 70 V for 2 hrs.
Afterward, the proteins were transferred to a polyvinyli-
dene fluoride membrane (Bio-Rad, USA) for 75 mins at
145 mV and 4°C. The membrane was blocked in 5% milk
powder (diluted in sodium Tris-buffer) for 1 hr and then
incubated with the primary antibody overnight at room
temperature. The primary antibody concentrations were
used as in the following: mouse monoclonal anti β-actin
antibody (1:1,000; Sigma, A5441), rabbit polyclonal anti
EP3-antibody (1:2000; ab117998, Abcam), rabbit polyclo-
nal anti p-ERK1/2 antibody (1:500; Abcam, ab47339) and
rabbit polyclonal anti Gi1-protein antibody (1:500; Novus
Biologicals, NBP2-16558). After washing the membranes
three times for 10 mins in TBS/Tween, the samples were
Table 1 Breast cancer cell lines used in this study: The breast cancer cell lines used in this study including their biological
characteristics are listed
Name Tissue Age Disease ER/PR Her2
SK-BR-3 (ATCC® HTB-30TM) Pleural effusion 43 years Adenocarcinoma Negative Positive
T-47D (ATCC® HTB-133TM) Pleural effusion 54 years Ductal carcinoma Positive Negative
MDA-MB-231 (ATCC® HTB-26TM) Pleural effusion 51 years Adenocarcinoma Negative Negative
MCF7 (ATCC® HTB-22TM) Pleural effusion 69 years Adenocarcinoma Positive Negative
CAMA-1 (ATCC® HTB-21TM) Pleural effusion 51 years Adenocarcinoma Positive Negative
Dovepress Hester et al
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incubated with the secondary antibody (Goat-anti-rabbit/
mouse, 1:1,000, Jackson Immuno Research, UK) for 1 hr
at room temperature. Followed by another washing step
(3x10 min), the bands were dyed using the color develop-
ment substrate 5-bromo-4-chloro-3-indolyle phosphate/
nitroblue-tetrazolium chloride (BCIP/NBT, Promega) in
0.1-M Tris–HCl, 0.15-M NaCl for 10–30 mins. The blots
were scanned and analyzed using the GelScan V6.0 1D
Analysis Software (SERVA, Electrophoresis GmbH,
Heidelberg, Germany). The differential integrated density
(absolute density minus background density) of the target
protein bands was normalized to the intensity of the house-
keeping protein bands of β-actin. The protein expression in
each stimulation group was normalized to the expression
in the unstimulated control groups. Every blot was
repeated three times.
BrdU-assay
SK-BR-3 and T-47D-cells were seeded in 96-well plates at
a density of 5×103 per well. After 24 hrs, the cell culture
medium was replaced by fresh medium containing 10, 100
or 1,000 nM of PGE2, of sulprostone, of L798,106, of
both sulprostone and L798,106 or DSMO 0.1% as a vehi-
cle control. After 72 hrs of incubation, the BrdU assay
(11647229001, Roche) was performed in accordance with
the manufacturer’s protocol. An Elx800 universal micro-
plate reader was used to measure the optical density at 450
nm, which is proportional to the cell proliferation rate.
Every experiment was repeated three times and the read-
ings were taken in triplicates for each concentration/con-
trol. The proliferation rate in each stimulation group was
normalized to the proliferation rate of the unstimulated
control group.
Scratch (wound healing) assay
To study the cell migration in vitro, 1.4×105 SK-BR-3
cells per well were seeded in 48-well plates and incubated
overnight to create a consistent monolayer. After 16 hrs, a
200 μL pipette tip was used to create an artificial gap
(“scratch”). The cells were washed three times with 1.5
mL DPBS (Gibco,USA). Afterward, 1 mL RPMI medium
+GlutaMAX containing 100 nM or 1,000 nM of PGE2, of
sulprostone, of L798,106 or of both sulprostone and
L798,106 were added to each well. DMSO 0.1% served
as a vehicle control. An inverse phase contrast microscope
(Leica Dmi1, Leica, Wetzlar, Germany) with an integrated
camera (LEICA MC120 HD, Leica, Wetzlar, Germany)
was used to capture images at 0, 24 and 48 hrs to monitor
the cell migration. The wound closure area was measured
using the software ImageJ and normalized to the wound
closure area in the unstimulated control group.
ELISA
The cAMP levels in SK-BR-3 cell lysates were measured
using an enzyme-linked immunosorbent assay kit (R&D
system, KGE012B, Minneapolis, USA). Each lysate con-
tained 6×106 cells. The assay was performed following the
protocol provided by the manufacturer. The results were
converted into ng/mL. The cAMP-levels in each stimula-
tion group were then normalized to the cAMP-levels in the
control group.
Statistics
The data analysis was performed using Microsoft Excel
and SPSS software. The figures were created with SPSS
software and Microsoft PowerPoint. The data were ana-
lyzed for statistical significance using the Mann–
Whitney-U-test, p-values≤0.05 were considered statisti-
cally significant and are marked with asterisks (*) in the
figures. The figures in this manuscript show means of at
least three independent experiments (except for mRNA-
levels, mean of two experiments) plus the standard error
of the mean.
Results
EP1 and EP3 receptor expression on
breast cancer cell lines
Recently, we observed that EP3 receptor expression is a posi-
tive prognostic marker in sporadic breast cancer.22 In this
study, we evaluated the EP3 expression on breast cancer cell
lines to find an adequate cell culture model for the analysis of
EP3 receptor-related functions. Five different breast cancer
cell lines were screened on the mRNA-level for their EP3
expression (Figure 1A). Based on the mRNA EP3-levels, we
chose the T-47D cell line as a cell culture model for tumors
with high EP3 expression. The mean protein expression of
EP3 on T-47D cells was 77.7% (normalized to β-actin as a
loading control, Figure 1B).
MCF-7 cells showed the second highest mRNAEP3-level.
As we had excluded MCF-7 from further experiments during
the project due to the lacking EP1 expression, we did not test
the protein EP3 expression on MCF-7 cells. MDA-MB-231
cells showed the lowest EP3 expression on mRNA level,
however, on protein level, an expression of EP3 could be not
detected. Therefore, we chose SK-BR-3 cells as a cell culture
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model for tumors with low EP3 expression. On protein level,
the mean EP3 expression on SK-BR-3 cells was 48.7%
(normalized to β-actin as a loading control, Figure 1B).
For stimulation, we used PGE2 as the physiological, unspe-
cific agonist to the EP3 receptor and to the other EP receptors
and the specific EP3 antagonist L798,106. As a specific EP3
agonist was not available, we worked with the not highly
selective EP1/3 agonist sulprostone. To evaluate which sulpros-
tone-induced effects might be mediated via the EP1 receptor,
we analyzed EP1 expression on the selected cell lines. On
mRNA-level, SK-BR-3 and MDA-MB-231 cells showed a
positive EP1 expression (Figure 1C). On protein level, SK-
BR-3 cells showed a mean EP1 expression of 132% (normal-
ized to β-actin as a loading control). As we had excluded the
MDA-MB-231 cell line from further experiments due to the
lacking protein EP3 expression, we did not test the protein EP1
expression onMDA-MB-231 cells. T-47D andMCF-7 cells did
not express EP1 on mRNA level (Figure 1C). T-47D cells did
also not express EP1 on protein level (Figure 1D). We did not
test protein EP1 expression on MCF-7 cells, as we had
excluded this cell line from further experiments as described
above.
EP3 antagonist significantly reduced EP3
expression on SK-BR-3 cells
Initially, we evaluated the feedback of targeting EP3 on its
expression. Hence, we measured protein EP3 expression on
SK-BR-3 and T-47D cells treated with 10, 100 or 100 nM of
PGE2, of the EP1/3 agonist sulprostone or of the EP3
antagonist L798,106. Both PGE2 (mean EP3 expression
111%, p=0.487 for all conditions) and sulprostone (mean
EP3 expression 102%, p=0.487 for all conditions) did not
significantly influence the EP3 expression on SK-BR-3
cells. L798,106 treatment significantly reduced the EP3
expression on SK-BR-3 cells (Figure 2). 10 nM of
L798,106 reduced the EP3 expression to 75% (p=0.037),
100 nM to 73% (p=0.487) and 1,000 nM to 68% (p=0.037).
All p-values reflect the comparison with the EP3 expression
of the unstimulated control group (Figure 2).
On T-47D cells, no alterations of EP3 expression after
targeting EP3 could be shown at all. Under all conditions
(PGE2, sulprostone, L798,106), the EP3 expression ranged
between 81% and 134% without any significant differences
(Figure S1).
Figure 1 EP1 and EP3 receptor expression in breast cancer cell lines. (A) EP3 mRNA-levels in the breast cancer cell lines MDA-MB-231, CAMA-1, T-47D, SK-BR-3 and
MCF7, n=2. (B) Relative EP3 protein-levels in the breast cancer cell lines T-47D, SK-BR-3 and MDA-MB-231. Top: mean+SEM, n=3, normalized on β-actin. Bottom:
representative Western blots of EP3 and β-actin. T-47D shows high, SK-BR-3 low, MDA-MB-231 no detectable EP3 protein expression. (C) EP1 mRNA-levels in the breast
cancer cell lines MDA-MB-231, CAMA-1, T-47D, SK-BR-3 and MCF7. (D) Relative EP1 protein-levels in the breast cancer cell lines T-47D and SK-BR-3. Top: mean + SEM,
n=3, normalized on β-actin. Bottom: representative Western blots of EP1 and β-actin. SK-BR-3 shows high, T-47D no detectable EP1 protein expression.
Dovepress Hester et al
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EP1/3 agonist, EP3 antagonist and the
combination of both significantly reduced
the proliferation of SK-BR-3 cells
The BrdU-assay was used to assess the cell proliferation rate
of SK-BR-3 and T-47D cells after stimulation with 10, 100
or 1,000 nM of PGE2, of the EP1/3 agonist sulprostone, of
the EP3 antagonist L798,106 or of the combination of both
agonist and antagonist. In SK-BR-3 cells, PGE2 treatment
did not show consistent effects on the proliferation (at 10
nM, proliferation 100%, p=0.48, at 100 nM: 96%, p=0.034,
at 1,000 nM: 99%, p=0.487). Treatment with sulprostone,
L798,106 or the combination of both significantly reduced
the cell proliferation of SK-BR-3 cells (Figure 3). 10 nM of
sulprostone decreased the proliferation of SK-BR-3 cells to
90% (p=0.037), 100 nM to 88% (p=0.037) and 1,000 nM to
88% as well (p=0.037). 10 nM of L798,106 reduced the
proliferation to 88% (p=0.037), 100 nM to 86% (p=0.034)
and 1,000 nM to 91% (p=0.037). 10 nM of both sulprostone
and L798,106 reduced the proliferation of SK-BR-3 cells to
92% (p=0.037), 100 nM to 94% (p=0.037) and 1,000 nM to
96% (p=0.053). All p-values reflect the comparison with the
proliferation rate of the unstimulated control group.
The combined treatment with both the EP1/3 agonist
and the EP3 antagonist did not cause significantly different
proliferation rates than the treatment with either the ago-
nist or the antagonist alone (exception: the treatment with
100 nM of both sulprostone and L798,106 resulted in a
slightly, but significantly higher proliferation rate than the
treatment with 100 nM of L798,106 alone, p=0.046).
In T-47D cells, the treatment with PGE2, sulprostone
or L798,106 did not result in significant changes in the cell
proliferation rate. The cell proliferation ranged from 91%
to 103% without any significant differences (exception: the
treatment with 1,000 nM sulprostone lead to a prolifera-
tion rate of 91% which was significantly lower than in the
control group; p=0.037, see Figure S2).
EP1/3 agonist, EP3 antagonist and the
combination of both significantly reduced
the migration of SK-BR-3 cells
Since EP3 targeting resulted in a significant reduction of
the cell proliferation of SK-BR-3 cells, we investigated
their migration ability using a functional wound healing
assay. SK-BR-3 cells were treated with 100 or 1,000 nM
of PGE2, of sulprostone, of L798,106 or of a combination
of both agonist and antagonist for 24 or 48 hrs. PGE2
treatment did not result in a significantly changed cell
migration (mean migration rate after the treatment 91%,
p=0.487 for both concentrations). The treatment with sul-
prostone, L798,106 or the combination of both signifi-
cantly reduced the SK-BR-3 cell migration (Figure 4).
After 24 hrs, 100 nM of sulprostone reduced the migration
Figure 2 EP3 receptor expression in SK-BR-3 cells after stimulation. Mean relative EP3 protein expression (n=3)+SEM in SK-BR-3 cells after stimulation with 10, 100 or
1,000 nM of PGE2, sulprostone and L798,106 is shown. Relative expression is normalized to β-actin and to the expression of the control group. *p≤0.05, comparing each
stimulation condition to the control group. EP3-antagonism causes a significant reduction of the EP3-expression compared to the control group.
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rate to 48% (p=0.037) and 1,000 nM to 49% (p=0.037).
100 nM of L798,106 reduced the migration rate to 54%
(p=0.037) and 1,000 nM to 41% (p=0.037). 100 nM of
both sulprostone and L798,106 reduced the migration rate
of SK-BR-3 cells to 65% (p=0.037) and 1,000 nM of both
to 55% (p=0.037). All p-values reflect the comparison with
the migration rate of the unstimulated control group.
The combined treatment with the EP1/3 agonist and the
EP3 antagonist did not cause significantly different migra-
tion rates than the treatment with either the agonist or the
antagonist alone.
Due to the lacking ability of T-47D cells to migrate
into a mechanically created scratch area, the migration
assay could not be performed for T-47D cells. As T-47D
cells had not reacted functionally on EP3 targeting in the
proliferation assay and furthermore, T-47D cells were also
lacking EP1 expression, we decided not to test T-47D in
the following experiment.
As the combined treatment with the EP1/3 agonist and
the EP3 antagonist had not led to different results than the
treatment with either one alone, we also decided not to test
the combination in the following experiment.
EP1/3 agonist and EP3 antagonist
decreased Gi-protein expression and
increased cAMP levels in SK-BR-3 cells
Known EP3-related pathways include the signaling via a
Gi-protein-AC-cAMP pathway, but also the phosphoryla-
tion of ERK1/2 to phosphorylated ERK1/2 (p-ERK1/2).
We therefore investigated whether the previously
described functional effects might be accompanied by
variations in the expression levels of these signaling mole-
cules. We analyzed Gi-protein and p-ERK1/2 expression
levels in SK-BR-3 cells treated with 10, 100 or 1,000 nM
of PGE2, of the EP1/3 agonist sulprostone or of the EP3
antagonist L798,106. We also determined the cAMP con-
centrations in the respective cell culture supernatants.
The Gi-protein expression in SK-BR-3 cells was not
significantly changed by PGE2 treatment (mean expres-
sion 106%, p=0.487 for all concentrations). The treatment
with sulprostone or with L798,106 reduced the Gi-protein
expression in SK-BR-3 cells significantly (Figure 5A). 10
nM of sulprostone reduced the Gi-protein expression to
71% (p=0.037), 100 nM to 69% (p=0.037) and 1,000 nM
Figure 3 Proliferation of SK-BR-3 cells after stimulation. Mean relative proliferation (n=3)+SEM of SK-BR-3 cells after stimulation with 10, 100 or 1,000 nM of PGE2, sulprostone,
L798,106 or both sulprostone and L798,106 is shown. Proliferation rate is normalized to the proliferation rate of the control group. *p≤0.05, comparing each stimulation condition
to the control group. EP3 antagonism, EP1/3 agonism and the combination of both all cause a significant reduction of the cell proliferation compared to the control group.
Dovepress Hester et al
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to 57% (p=0.037). 10 nM of L798,106 reduced the Gi-
protein expression to 70% (p=0.037), 100 nM to 80%
(p=0.037) and 1,000 nM to 77% (p=0.037). All p-values
reflect the comparison with the Gi-protein expression in
the unstimulated control group.
The cAMP concentrations in SK-BR-3 cell culture
supernatants were partly reduced by PGE2 treatment
(Figure 5B; 10 nM of PGE2: cAMP level 98%, p=0.48.
100 nM of PGE2: 87%, p=0.037. 1,000 nM of PGE2:
86%, p=0.037). The treatment with sulprostone or with
L798,106 increased the cAMP levels produced by SK-
BR-3 cells significantly. 10 nM of sulprostone increased
the cAMP level to 105% (p=0.037) and 100 nM to 107%
(p=0.037, no significant increase by treatment with 1,000
nM of sulprostone, cAMP level 99%, p=0.487). 10 nM of
L798,106 increased the cAMP concentration significantly
to 111% (p=0.037) and 1,000 nM not significantly to
104% (p=0.487). The results of the stimulation with 100
nM of L798,106 are not shown due to technical issues
with this sample. All p-values reflect the comparison with
the cAMP concentration in the supernatants of the unsti-
mulated control cells.
The p-ERK1/2 expression in SK-BR-3 cells was not
significantly changed by PGE2 treatment (mean expres-
sion 99.7%, p=0.487 for all concentrations, Figure 5C).
The treatment with 10 nM of sulprostone reduced the p-
ERK1/2 expression to 84% (p=0.037), but the other con-
centrations of sulprostone did not change the p-ERK1/2
expression significantly (100 nM of sulprostone: p-ERK1/
2 expression 102%, p=0.487, 1,000 nM of sulprostone:
88%, p=0.487). Treatment with 100 nM of L798,106
increased the p-ERK1/2 expression significantly to 133%
(p=0.037); 10 and 1,000 nM not significantly to 130%
(p=0.487) and 151% (p=0.317), respectively. All p-values
reflect the comparison with the p-ERK1/2 expression in
the unstimulated control group.
Figure 4 Migration of SK-BR-3 cells after stimulation. Top: mean relative migration (n=3)+SEM of SK-BR-3 cells after stimulation with 100 or 1,000 nM of PGE2,
sulprostone, L798,106 or both sulprostone and L798,106 for 24 hrs is shown. Migration rate is normalized to the migration rate of the control group. *p≤0.05 comparing
each stimulation condition to the control group. Bottom: representative images show SK-BR-3 cell migration into the scratched area after stimulation with 100 nM PGE2,
sulprostone, L798,106 or both sulprostone and L798,106 for 48 hrs compared to before stimulation (0 hr). EP3 antagonism, EP1/3 agonism and the combination of both all
cause a significant reduction of cell migration compared to the control group.
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Discussion
Elevated levels of PGE2 caused by COX-2 overexpression
are known important factors in breast cancer carcinogen-
esis. However, studies concerning the role of the EP
receptors 1–4 are still rare and the results are conflicting.
A recent study of our group showed that EP3 receptor
expression in sporadic breast cancer is a positive prognos-
tic factor regarding progression-free and overall survival.22
This present study aimed to find explanations for the
observed positive prognostic effect of high EP3 receptor
expression by analyzing functional aspects of breast can-
cer cells after targeting EP3.
To find adequate cell culture models that represent EP3
positive and negative breast tumors, we screened five
different breast cancer cell lines for their EP3 expression
on mRNA-level and on protein-level. T-47D cells showed
the highest EP3 expression on both mRNA- and protein-
level. MDA-MB-231 cells showed the lowest mRNA EP3
expression, but a protein EP3 expression could not be
detected. The antibody we used detects a specific isoform
of EP3. As discussed below, EP3 exists in different
isoforms created by alternative splicing31 and the MDA-
MB-231 cell line might express an isoform we could not
detect by the antibody we used. Therefore, we chose the
SK-BR-3 cell line, that showed both the second lowest
mRNA EP3 expression and a low EP3 protein-level, for
our functional analysis.
We initially aimed to target the EP3 receptor with a
specific EP3 agonist to analyze EP3 related cell functions.
However, a specific EP3 agonist was not available.
Therefore, we chose to stimulate the breast cancer cells
with the physiological PGE2, with a specific EP3 antago-
nist named L796,106 and with the dual EP1/EP3 agonist
sulprostone. Since we treated cells with a dual EP1/EP3
agonist, we evaluated the EP1 receptor expression on our
selected cell culture models SK-BR-3 and T-47D prior to
our functional experiments. This was essential to deter-
mine whether sulprostone-related effects might be not only
due to EP3 but also due to EP1 signaling. T-47D cells did
not express EP1 at all, while in SK-BR-3 cells an EP1
expression could be shown on both the mRNA- and the
protein-level.
Figure 5 EP3 signaling-related molecules in SK-BR-3 cells after stimulation: mean relative protein expression/relative concentration levels (n=3)+SEM in SK-BR-3 cells after
stimulation with 10, 100 or 1,000 nM of PGE2, sulprostone and L798,106 are shown. (A) Top: rRelative Gi-protein expression, normalized to β-actin and the to the Gi-
protein expression in the control group: EP3 antagonism and EP1/3 agonism cause a significant reduction of Gi-protein expression. Bottom: exemplary Western blots (WB)
of Gi-protein and β-actin in the control group and after stimulation with 10 nM of PGE2, sulprostone or L798,106 (B) Relative cAMP-concentration, normalized to the
cAMP-concentration in the control group: EP3 antagonism and EP1/3 agonism show a trend to elevated cAMP levels, PGE2 reduces cAMP levels. Stimulation with 100 nM
L798,106 is not shown due to technical issues with this sample. (C) Top: relative p-ERK1/2-expression, normalized to β-actin and to the p-ERK1/2 expression in the control
group: EP3 antagonism shows a trend to induced pERK-1/2 expression. Bottom: representative Western blots of p-ERK-1/2 and β-actin in the control group and after
stimulation with 10 nM of PGE2, sulprostone and L798,106.
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To evaluate the feedback of targeting EP3 on its
expression, we analyzed the EP3 expression on SK-BR-3
and T-47D cells after stimulation with the predefined
agents. No feedback regulation on the EP3 expression
could be seen on T-47D cells and on SK-BR-3 cells treated
with agonists (PGE2, sulprostone). However, EP3 antag-
onism did significantly reduce the EP3 expression on SK-
BR-3 cells. We could not find a demonstration of this
negative feedback mechanism in previously published
studies.
The main analysis of this study was the evaluation of
functional alterations after targeting the EP3 receptor in
breast cancer cell lines. The T-47D cell line did not react
functionally on EP3 targeting. Therefore, in T-47D cells –
even if the EP3 expression was high – the EP3 pathway
might not have a significant role in tumor cell biology.
This might be caused by the differential expression of
various EP3 isoforms in different tumor cell lines, as
discussed below.
In the SK-BR-3 cell line, however, EP3 antagonism led
to significantly reduced proliferation and migration rates
compared to unstimulated cells. This suggests that the EP3
receptor might be a receptor that contributes to tumor
growth and metastasis after being stimulated. Concerning
these effects, SK-BR-3 breast cancer cells were biologi-
cally similar to other gynecological tumor cells like endo-
metrial carcinoma cells. EP3 antagonism has already been
shown to reduce cell proliferation and migration of endo-
metrial carcinoma cells.24 But in endometrial carcinoma
patients, a high EP3 expression was clinically associated
with impaired overall survival as well,24 while EP3
expression was a positive prognostic factor in breast
cancer.22 SK-BR-3 is a breast cancer cell line that over-
expresses the Her-2 protein. In our previous clinical study
concerning the prognostic relevance of EP3 in breast can-
cer, we could not observe a correlation between Her-2
overexpression and EP3-positivity.22 EP3 positivity was a
significant prognostic factor for improved overall survival
in both the overall and the Her-2-negative cohort.
However, it did not show significant prognostic relevance
in the Her-2-positive cohort. This might explain why the
biologically tumor-promoting effects of EP3 in SK-BR-3
cells could be contrary to our previously observed clinical
effect of high EP3 expression as a positive prognostic
factor in breast cancer.
Similar tumor-promoting effects of the EP3 receptor
have been demonstrated in other tumor entities. In squa-
mous carcinoma cells, the treatment with an EP3
antagonist (ONO-AE-240) reduced the cell growth.32 A
group investigating EP3 linked effects on lung cancer
tumorigenesis showed that injection of Lewis lung carci-
noma cells in EP3-knockout mice compared to EP3-wild-
type mice led to a reduced colony formation of carcinoma
cells,33 a reduced angiogenesis,34 lymphangiogenesis35
and a reduced tumor growth.34,35 EP3 inhibition in a
non-small cell lung cancer cell line reduced the migration,
the invasion and the viability and EP3 silencing in mice
strongly reduced the tumor growth, the tumor volume and
the tumor metastasis of non-small cell lung cancer.36
Consistent with this data, tumor angiogenesis could be
induced by treatment of Lewis lung carcinoma cells with
the selective EP3 agonist ONO-AE-248.34 Demonstrated
mechanisms of EP3 signaling include the upregulation of
matrix metalloproteinase-9 and of vascular endothelial
growth factor.33,35 In accordance with our results, all
these studies suggest a tumorigenic ability of EP3 and
consequentially an anti-tumorigenic effect when inhibited.
In contrast, one further study showed that treatment of
breast cancer cells with an EP3 antagonist before injecting
them into mice did not have any effect on tumor metastasis.37
In prostate cancer, EP3 antagonism increased tumor growth
in vitro, indicating a protective effect of EP3 signaling.38
Consistent with this data, the overexpression of EP3 in
prostate cancer cells decreased the tumor growth in vitro
and sulprostone seemed to enhance this inhibitory effect.39
However, regarding this study, the non-selective binding of
sulprostone to both the EP1 and the EP3 receptor has to be
considered. EP3 agonism also reduced the ability of inflam-
matory breast cancer cells to undergo vasculogenic mimicry,
a characteristic of very aggressive tumors.40
In summary, the published EP3-related effects vary and
seem to be tissue and cell type specific. Different intracel-
lular pathways might be activated, as discussed below.
As described, EP3 antagonism significantly reduced the
cell proliferation and migration of SK-BR-3 cells. However,
the treatment with the EP1/3 agonist sulprostone led to a
similar result, with a decrease in proliferation and migration
rates, as well. Sulprostone is a non-selective EP3 agonist, it
is in fact a dual EP1/3 receptor agonist.29 Consequentially,
sulprostone-related effects may occur due to EP1 or due to
EP3 agonism. Our data suggest that sulprostone’s effects on
breast cancer cells are stronger related to EP1 than to EP3
signaling, suggesting an anti-tumorigenic effect of EP1 sig-
naling. In contrast to EP3, the EP1 receptor acts through
phospholipase C/inositol triphosphate signaling, leading to
increased intracellular calcium levels.16
Hester et al Dovepress
submit your manuscript | www.dovepress.com
DovePress































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
However, data about the effect of EP1 signaling regard-
ing carcinogenesis are contradictory. A tumorigenic poten-
tial of the EP1 receptor could be shown for breast, colon and
skin cancer.20,41,42 In contrast to these findings and in
accordance with our data, the treatment of breast cancer
cells with an EP1 antagonist or silencing EP1 in these cells
before injecting them into a murine model, led to an
increased amount of lung colonies. This suggests an impor-
tant effect of EP1 in preventing metastasis.21 The same
group showed an impaired overall survival of breast cancer
in women lacking nuclear EP1 expression.21 However,
possible varying effects of EP1 signaling in the primary
tumor and in metastases need to be considered.
To clarify if a combination of the EP3 antagonist with the
EP1/3 agonist would further impair SK-BR-3 cell functions,
we also treated SK-BR-3 cells with a combination of both
agents. We could demonstrate that the combined treatment
with both the agonist and the antagonist also reduced cell
proliferation and migration of SK-BR-3 cells. However, no
further impairment of the proliferation and the migration
compared to the treatment with the single agents could be
seen. We suppose that when combining both agents, negative
feedback or interaction mechanisms might be activated that
prevent the further impairment of cell functions. Further
studies using gene silencing strategies will contribute to
improve our understanding of these mechanisms.
Figure 6 EP3-related effects in SK-BR-3 cells. The proposed functional effects and mechanisms shown in this study are summarized. The EP3-antagonist L798,106 reduces
cell proliferation and migration of SK-BR-3 cells possibly by reducing the Gi-protein expression and consecutively elevating cAMP. A phosphorylation of ERK1/2 to p-ERK1/2
might play a role as well. Sulprostone (EP1/3-agonist) related effects are possibly more related to EP1-signaling.
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It seems that EP3 (and EP1) related effects are tissue and
cell type specific. Contrarieties of these effects may also be
due to varying expression of EP3 isoforms. The human EP3
gene consists of ten exons and nine introns that form at least
eight isoforms via alternative mRNA splicing.31 These splice
variants are characterized by different cytoplasmic C term-
inal tails. As a result, the EP3 receptor is capable of signaling
via decreasing or increasing cAMP levels by activating sti-
mulatory or inhibitory G proteins.43 Data from the literature
suggest that EP3 mainly signals via an inhibitory G-protein
followed by decreased cAMP levels. However, the tissue
distribution of the EP3 isoforms is still unknown.44 This
might partly explain the contradictory results of the above-
named studies targeting EP3.
Besides the Gi-protein coupled pathway, EP3 is also
capable to signal via PI3K and ERK.28
To examine which pathway seemed to be influenced the
most in SK-BR-3 cells and could possibly explain the
reduced proliferation and migration rates shown in our
study, we examined Gi-protein expression, cAMP levels
and p-ERK1/2 protein expression. After treatment of SK-
BR-3 cells with the EP3 antagonist, we could see a signifi-
cant reduction of the Gi-protein expression and a trend to
increased cAMP levels. This suggests that the functional
effects measured in our previous experiments might be
mainly due to signaling via the Gi protein-AC/cAMP
coupled pathway. Signaling via p-ERK1/2 seems to be
less relevant as no significant changes, but only a small
trend to induced p-ERK1/2 levels could be shown.
Contradictory our findings, Ma et al did not see any
cAMP level changes in the murine mammary tumor cells
lines 410.4, 410 and 66.1 after stimulation with a specific
EP3 antagonist (ONO-AE-208).37 Stimulating MDA-MB-
231 cells with a cAMP analog has been shown to inhibit cell
migration.45 Similar results could be shown for pancreatic
cancer cells, indicating a protective potential of cAMP
regarding cell motility and invasiveness.46 In MCF-7 breast
cancer cells, cAMP increases estrogen-receptor (ER) beta
expression which inhibits estradiol-induced proliferation
and migration of breast cancer cells.47 So, the reduced
proliferation and migration of SK-BR-3 cells observed in
this study - in combination with a Gi-protein decrease an
induction of cAMP - might be caused by cAMP-mediated
effects like ER beta induction. Similarly, in cervical cancer
cells, a cAMP-dependent increase of ER-beta transcription
has been described. However, further studies using gene
silencing strategies and inhibitors to the Gi/cAMP-pathway
will have to clarify these mechanisms.
Taken together, we could demonstrate a significant
reduction of SK-BR-3-cell proliferation and migration
due to EP3 antagonism, as summarized in Figure 6.
This might be caused by a decrease of Gi-protein
expression and an increase in cAMP levels. Clearly,
our study provides only a preliminary insight into the
EP3 signaling in the SK-BR-3 breast cancer cell line
and further experiments are necessary to confirm the
signaling pathway.
Conclusion
We observed that even if EP3 expression is a clinically
positive prognostic factor in breast cancer patients, this
cannot be explained by EP3-related effects in tumor cell
biology. In accordance with other gynecological tumor
entities, eg, endometrial carcinoma cells,24 EP3 antagon-
ism in breast cancer cells leads to decreased proliferation
and migration, possibly due to an Gi-protein-cAMP path-
way. This suggests that the positive prognostic effect of
EP3 might not be explained by tumor cell biology, but by
other aspects, like immunological factors in the tumor
environment. Our further studies aim to identify these
factors to clarify the potential of EP3 as prognostic and
therapeutic target in breast cancer.
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Supplementary material
Figure S1 EP3 expression on T-47D cells after stimulation. Mean relative EP3 expression (n=3)+SEM in T-47D cells after stimulation with 10, 100 or 1,000 nM of PGE2,
sulprostone or L798,106 is shown. Relative expression is normalized to β-actin and to the EP3 expression in the control group. The EP3 expression is not significantly
influenced by any stimulation condition.
Figure S2 Proliferation of T-47D cells after stimulation. Mean relative proliferation (n=3)+SEM of T-47D cells after stimulation with 10, 100 or 1,000 nM of PGE2,
sulprostone or L798,106 is shown. Proliferation rate is normalized to the proliferation rate of the control group. *p≤0.05, comparing each stimulation condition to the
control group. Proliferation is not clearly influenced by stimulation.
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